Elevated Lp(a) in People at Risk of or with Established Heart Disease or Stroke
Upcoming
-
Adelaide SA
Effect of Muvalaplin tablet on the reduction of major adverse cardiovascular events in adults with elevated Lipoprotein(a), who have had a prior atherosclerotic cardiovascular event, or are at risk for a first atherosclerotic cardiovascular event.
- Age > 18 years
- Lp(a) blood test taken at pre-screening or screening visit
- Oral tablet taken daily
- History of coronary artery disease (heart attack, bypass grafts or stroke) OR
- History of peripheral artery disease (amputation, stents in legs) OR
- At risk of having a coronary or peripheral arterial event (need to have 4 risk factors)
Payment / Remuneration
- Reimbursed for travel
Information for Practitioners
- Lp(a) blood test taken at screening visit
- History of ASCVD event >90 days >10 years prior to screening OR
- At risk of first ASCVD event - must have at least 4 defined risk factors, assessed at pre-screening/screening visit
- Exclusion - planned coronary, carotid or peripheral arterial revasc or surgery after randomisation
- No uncontrolled hypertension: SBP>180mmHg, DBP>110mmHg
- No history of cancers within 5 years of screening (some exceptions)